Benzinga | Sep 10, 2021 07:35PM EDT

Synlogic Presents Data On SYNB8802 For Enteric Hyperoxaluria At American Urological Association (AUA) Annual Meeting

Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present data on SYNB8802, an investigational Synthetic Biotic medicine for the treatment of Enteric Hyperoxaluria (HOX), during the American Urological Association (AUA) Annual Meeting, being held virtually September 10 -- 13th.

Title: Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary Hyperoxaluria

Abstract Number: 21-6087

Synlogic will share previously communicated results of the SYNB8802 Phase 1A study including:

* SYNB8802 was generally well tolerated in healthy volunteers. There were no serious or systemic adverse events. The most frequent adverse events were mild or moderate, transient, and GI-related.

* Dietary Hyperoxaluria was successfully induced in healthy volunteers.

* Dose-responsive changes in urinary oxalate levels were observed with a significant reduction in urinary oxalate relative to placebo across three dose levels.

* A dose of 3e11 live cells administered three times daily with meals was selected as the dose for Part B of the study. This dose was well-tolerated and resulted in a 28.6% (90% CI: -42.4 to -11.6) reduction from baseline urinary oxalate levels compared to placebo.

* At the end of dosing, the mean 24-hour urinary oxalate level was 40.1 mg for subjects treated with SYNB8802 3e11 live cells, compared to 58.1 mg for placebo subjects. Upper limit of normal urinary oxalate levels are 45 mg per 24 hours.

Learn more about Synlogic's programs and pipeline by visiting https://www.synlogictx.com/.